Reporter brief
Metformin versus placebo RCT examining effects on longevity gene expression and inflammation in prediabetes.
What happened
This randomized placebo-controlled trial tested metformin 500 mg three times daily for 2 months in prediabetic subjects. The study aimed to measure expression of longevity-related genes (SIRT1, p66Shc, p53, mTOR) in peripheral blood mononuclear cells, monocyte polarization markers, and inflammatory cytokines. No results are reported in this abstract.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Pre-diabetic individuals
- Design
- Rct
- Sample
- —
- Journal
- University of Padova
- Published
- Mar 13, 2013
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.